Replies to post #799243 on NorthWest Biotherapeutics Inc (NWBO)

[learningcurve2020]

What do you think you just pop some patient’s culture into an Eden and you get instant savings? It’ll take years to promote and coordinate for batch production where perhaps the cost savings will eventually show itself.

[JerryCampbell]

What if MHRA requires equivalency testing?

nwbo has certainly warned of that possibility in its SEC filings.

[dennisdave]

I would think NW can submit appraisal based on Flaskworks right after approval and if they have to use artisan methods and sell at discount till EDEN/Flaskworks is up and validated , it is still better than delaying approval by 6-12 months. Agreed. :)

So NWBO would invest about $15 million in C lab manual production and then just discard that investment to save nine months, simply to keep iHub longs happy.
And you’re all ignoring the fact that NWBO’s last PR literally stated that commercial DCVax-L production will use Eden/Flaskworks in C which is the only thing that matters for the MHRA for the MA.

“The Company views use of the Flaskworks closed system as key to enabling DCVax-L production to begin taking place in Grade C suites… and views such transition as central to large-scale commercial production.”

lalalla ignore ignore ignore

Alllllrighty then

All of you claiming that the idea that the method by which DCVax-L is manufactured would be MHRA irrelevant is just mind-boggling..

Whatever helps you sleep at night.